# The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

> **NCT03685773** · PHASE2 · WITHDRAWN · sponsor: **Albert Einstein College of Medicine**

## Conditions studied

- Diabetes Mellitus, Type 2
- Glucose, High Blood
- Glucose Metabolism Disorders

## Interventions

- **DRUG:** Diazoxide
- **DRUG:** Placebo (for diazoxide)
- **DRUG:** Nicotinic acid

## Key facts

- **NCT ID:** NCT03685773
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-04-21
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-04-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Permanently terminated due to COVID-19 given the poor vaccine penetrance in liver transplant recipients.

This is not a suspension of IRB approval.
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03685773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03685773, "The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03685773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*